

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

1-(2,3-Dideoxy-3-Fluoro- β -D-Ribofuranosyl)Tine (FDDT). Improved Preparation and Evaluation as a Potential Anti-Aids Agent

R. Sterzycki^a; M. Mansuri^a; V. Brankovan^b; R. Buroker^a; I. Ghazzouli^a; M. Hitchcock^a; J-P. Somrnadossi^c; J. C. Martin^a

^a Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, CT, U.S.A. ^b Oncogen, Seattle, WA, U.S.A. ^c U. of Alabama, Birmingham, AL, U.S.A.

To cite this Article Sterzycki, R. , Mansuri, M. , Brankovan, V. , Buroker, R. , Ghazzouli, I. , Hitchcock, M. , Somrnadossi, J-P. and Martin, J. C.(1989) '1-(2,3-Dideoxy-3-Fluoro- β -D-Ribofuranosyl)Tine (FDDT). Improved Preparation and Evaluation as a Potential Anti-Aids Agent', *Nucleosides, Nucleotides and Nucleic Acids*, 8: 5, 1115 – 1117

To link to this Article: DOI: 10.1080/07328318908054302

URL: <http://dx.doi.org/10.1080/07328318908054302>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

1-(2,3-DIDEOXY-3-FLUORO- β -D-RIBOFURANOSYL)THYMINE (FDDT).
IMPROVED PREPARATION AND EVALUATION AS A POTENTIAL
ANTI-AIDS AGENT

R. Sterzycki*, M. Mansuri, V. Brankovan¹, R. Buroker,
I. Ghazzouli, M. Hitchcock, J-P. Sommadossi² and J. C. Martin.
Bristol-Myers Company, Pharmaceutical Research and
Development Division, Wallingford, CT 06492, U.S.A.

¹Oncogen, Seattle, WA 98121, U.S.A.

²U. of Alabama, Birmingham, AL 35294, U.S.A.

SUMMARY: 3'-Deoxy-3'-fluorothymidine was prepared and evaluated as a potential anti-AIDS agent.


1-(2,3-Dideoxy-3-fluoro- β -D-ribofuranosyl)thymine (FDDT)¹ is, like AZT, a 3'-deoxy-3'-substituted thymidine (1) analog. Here we report two alternative synthetic approaches to FDDT.

For a large scale preparation 5'-protected-3'-threo-thymidine² (2) was treated with DAST.

Subsequent deprotection gave FDDT with up to 56% overall yield (5'-Tr protection). The protected elimination products (4) and (5) were also isolated and characterized.

In a small scale study 2,3'-anhydrothymidine (3) was opened with an excess of HF(Py) at 90 - 100°C (bath) to give FDDT with 30 - 40% yield.

FDDT was evaluated in HIV1 infected CEM cells and was found to be a potent inhibitor of viral replication (ED_{50} = 0.007 μ M - 0.1 μ M). FDDT toxicity in vitro was comparable to AZT in the cellular systems studied. Recently several groups^{3,4,5,6} evaluated FDDT against HIV1 in vitro.



FDDT-TP, the nucleotide believed to be responsible for the anti-HIV1 activity of FDDT, was prepared and evaluated as an inhibitor of HIV1 RT. The K_i value of FDDT-TP for DNA template was 84 μM and for RNA template was 0.26 μM .

In vivo toxicity was evaluated in the mouse model in a four week study. Death of experimental animals was observed at all investigated doses (oral administration, 100 - 1000 mg/kg/day).

REFERENCES

1. G. Etzold, et al., *Tetrahedron*, **27**, 2463, (1971).
2. J. P. Horwitz, et al., *J. Org. Chem.*, **28**, 942, (1963).
3. R. Datema, et al., 4th Int. Conf on AIDS, Stockholm, Sweden, **1988**.
4. E. Matthes, et al, *B. B. R. C.*, **153** (2), 825, (1988).
5. H. Hartmann, et al., *AIDS Research and Human Retroviruses*,
in press.
6. J. Balzarini, et al., *Bioch. Pharm.*, **37** (14), 2847, (1988).